Statistics for Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study.
Total visits
| views | |
|---|---|
| Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study. | 14 |
Total visits per month
| views | |
|---|---|
| January 2024 | 0 |
| February 2024 | 0 |
| March 2024 | 0 |
| April 2024 | 0 |
| May 2024 | 0 |
| June 2024 | 0 |
| July 2024 | 0 |
Top country views
| views | |
|---|---|
| United States | 9 |
| China | 3 |
| Thailand | 2 |
Top city views
| views | |
|---|---|
| Roanoke | 5 |
| Spring Hope | 3 |
| Phitsanulok | 2 |
| Chaohu | 1 |
| Hangzhou | 1 |
| Hongkou | 1 |